ANB030-204: Ulcerative Colitis
20240422192726

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Ulcerative Colitis Register Today!

mRNA-1283-P301 PART 2 Covid-19
20240324150828

A randomized, observer-blind, active-controlled Phase 3 study to investigate the safety, immunogenicity, and relative vaccine efficacy of mRNA-1283 compared with mRNA-1273 in participants aged ≥12 years for the prevention of COVID-19. Register Today!

B7981080
20240324145104

A phase 3 randomized, double-blind, 52-week placebocontrolled multi-center study with a double-blind 52-week extension period with randomized dose up/dose down titration investigating the efficacy, safety, and tolerability of Ritlecitinib in adult participants with nonsegmental vitiligo. Register Today!

Vaccine (RSV) – 222090 (extension to 212494)
20240322115259

A phase 3b, randomized, open label, multi-country, multi-center, extension and crossover vaccination study to evaluate the immunogenicity and safety of different revaccination schedules and persistence of a single dose of the RSVPreF3 OA vaccine in adults aged 60 years and above who participated in the RSV OA=ADJ-006 study. Register Today!

Atopic Dermatitis – M16-047 (extension to M18-891)
20231116141939

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis For more information, please click here. Register Today!

Alopecia Areata – M23-716
20230901140951

A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata Register Today!